Danish Medicines Council releases recommendations – mixed bag for Sanofi and BMS

Eight applications have been processed during the Danish Medicines Council’s March meeting, including submissions on indication expansions from Sanofi and Bristol Myers Squibb, both of which received both good and less-than-uplifting recommendations.
Photo: Stine Rasmussen/Ritzau Scanpix
Photo: Stine Rasmussen/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

On Wednesday last week, pharmaceutical firms Sanofi and Bristol Myers Squibb received a mixed bag of recommendations from Danish Medicines Council.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading